Health coverage company Centene (NYSE:CNC) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.9% year on year to $53.58 billion. The company’s full-year revenue guidance of $195.5 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP profit of $2.51 per share was significantly above analysts’ consensus estimates.
Is now the time to buy CNC? Find out in our full research report (it’s free for active Edge members).
Centene (CNC) Q2 CY2026 Highlights:
- Revenue: $53.58 billion vs analyst estimates of $47.39 billion (9.9% year-on-year growth, 13.1% beat)
- Adjusted EPS: $2.51 vs analyst estimates of $1.08 (significant beat)
- The company lifted its revenue guidance for the full year to $195.5 billion at the midpoint from $189.5 billion, a 3.2% increase
- Management raised its full-year Adjusted EPS guidance to $4.80 at the midpoint, a 41.2% increase
- Operating Margin: 2.2%, up from -0.9% in the same quarter last year
- Customers: 25.89 million, down from 26.27 million in the previous quarter
- Market Capitalization: $31.57 billion
StockStory’s Take
Centene’s second quarter was marked by clear operational improvements, yet the market reacted negatively, reflecting concerns about underlying trends. Management attributed the quarter’s outperformance to disciplined cost management and favorable risk adjustment in its Marketplace and Medicare businesses. CEO Sarah London cited enhanced execution in quality initiatives and efficiency gains, while noting that Medicaid membership declines were sharper than anticipated, largely due to state-driven eligibility tightening and preparation for regulatory changes.
Looking ahead, Centene’s raised guidance for the year is anchored in improved margin expectations for both Marketplace and Medicare prescription drug plans, as well as ongoing investments in technology and data analytics. Management emphasized that future performance will depend on their ability to navigate policy changes, Medicaid attrition, and evolving risk pools while maintaining cost discipline. CFO Drew Asher noted that further digitization and targeted AI investments are expected to drive operational efficiencies, stating, “We are very optimistic about our ability to deliver an industry-leading cost structure.”
Key Insights from Management’s Remarks
Management pointed to core segment execution and strategic cost reductions as key contributors to the quarter’s results, while also flagging Medicaid membership declines and regulatory complexity as important themes.
- Marketplace margin recovery: The Marketplace segment benefited from lower-than-expected medical costs and a favorable risk adjustment outcome, particularly among higher-acuity Silver tier members. This enabled a material upward revision in expected pretax margins for the year.
- Medicaid membership declines: Medicaid membership fell more than anticipated, driven by state-specific changes and stricter eligibility. Management is preparing for further attrition as new federal requirements (OB3) begin to take effect, which target expansion populations and introduce more stringent verification processes.
- Medicare segment stability: The Medicare business, including both Medicare Advantage and prescription drug plans (PDP), posted stable performance. PDP margins improved due to lower specialty drug utilization and successful risk adjustment settlements, while Medicare Advantage results were supported by a shift towards serving more dual-eligible (D-SNP) populations.
- Operational efficiencies and AI: Centene continued to optimize its cost structure by simplifying its organizational model and expanding AI use cases. Early wins in fraud detection and legal invoice review provided tangible cost savings, and the company is prioritizing scalable data and context platforms for future AI deployment.
- Behavioral health and payment integrity: Notable improvement in behavioral health cost trends within Medicaid was driven by targeted provider engagement, policy influence, and enhanced fraud detection algorithms. These efforts contributed to a more favorable medical cost trend and supported overall margin recovery.
Drivers of Future Performance
Centene’s outlook hinges on effective execution through regulatory transitions, technology-driven cost control, and managing the impact of membership shifts.
- Navigating Medicaid headwinds: Management anticipates continued Medicaid attrition as states implement OB3 requirements, but expects rate adjustments and targeted engagement programs to help offset higher acuity and maintain margin progression. The company’s ability to work with states on timely rate updates and support member eligibility is seen as critical.
- Marketplace pricing discipline: For 2027, Centene plans to sustain its margin restoration strategy in the ACA Marketplace by balancing competitive pricing with profitability. Management noted that market exits by competitors may offer growth opportunities, but risk adjustment and policy changes add uncertainty to membership trends.
- Technology and operational transformation: Ongoing investments in AI and digitization are expected to further reduce general and administrative expenses. Management emphasized that scalable data platforms and focused deployment of automation should both drive margin improvement and support compliance in a regulated environment.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be watching (1) the pace and impact of Medicaid membership attrition as OB3 requirements are phased in, (2) Centene’s ability to achieve further cost efficiencies through AI and operational streamlining, and (3) execution on Marketplace margin targets despite ongoing policy and risk adjustment uncertainties. Success will also depend on maintaining constructive state partnerships and adapting to evolving regulatory landscapes.
Centene currently trades at $62.46, down from $64.08 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Stocks That Trumped Tariffs
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.